India Coronavirus Vaccine Market By Type (mRNA Based, Non-Replicating Viral Vector Based, Inactivated Vaccine), By Patient Type (Adult, Pediatric), By End User (Hospitals, Clinics, Research Institutes, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

India Coronavirus Vaccine Market was values at USD 765.18 million in 2024 and is expected to USD 1259.90 Million by 2030, growing with a CAGR of 8.81% in the forecast period.  

Coronavirus vaccines are designed to protect against SARS-CoV-2, the virus causing COVID-19, by training the immune system to recognize and fight infection, thereby reducing disease severity. For instance, protein subunit vaccines like Novavax use harmless spike protein components to trigger antibody production.

In India, strong government-led vaccination campaigns significantly accelerated vaccine adoption and market growth. The country’s robust manufacturing ecosystem, led by players like Serum Institute of India and Bharat Biotech, enabled large-scale domestic supply and global exports.

Ongoing R&D, technological innovations, and high public awareness further supported vaccine uptake. Additionally, initiatives to achieve herd immunity and India’s vaccine diplomacy efforts strengthened its global position and contributed to overall market expansion..

Key Market Drivers

Pharmaceutical Innovation

Pharmaceutical innovation has been a major force behind the expansion of the India coronavirus vaccine market, because the country did not rely on a single scientific pathway and instead advanced across inactivated vaccines, viral vector platforms, protein subunit vaccines, DNA technology, and even intranasal delivery, which widened the range of options available for different age groups, use cases, and immunization strategies.

This broad innovation base helped India move from emergency response to long-term vaccine capability, supported by fast regulatory action, strong public research linkages, and manufacturing readiness that allowed new products to be developed and deployed at scale. Bharat Biotech expanded Covaxin manufacturing capacity to about 700 million doses a year across facilities in Hyderabad and Bengaluru, while Zydus said ZyCoV-D would be manufactured at 10 to 12 crore doses annually, showing how Indian companies invested not only in discovery but also in industrial scale-up. Biological E also strengthened the innovation landscape through Corbevax and stated that it had delivered 10 crore doses to the Government of India, reinforcing the role of large domestic manufacturers in broadening supply.

For instance, Bharat Biotech’s iNCOVACC was launched as the world’s first intranasal COVID vaccine for both primary series and heterologous booster use, giving India a distinctive innovation milestone that went beyond conventional injectable formats and added fresh momentum to vaccine development in the country. Together, these advances made India’s vaccine ecosystem more resilient, more adaptable to future health threats, and far more capable of sustaining demand through technology-led confidence and availability.

Increasing Public Awareness and Acceptance

Increasing public awareness and acceptance played a critical role in driving the India coronavirus vaccine market, because vaccine demand rose not only through availability but also through sustained communication that explained safety, benefits, eligibility, access points, and the public value of widespread immunization. India’s vaccination programme gained strength from repeated messaging by health authorities, digital coordination through CoWIN, and targeted outreach that reduced confusion and made vaccination easier to understand and access at scale.

The Economic Survey highlighted through official government communication that India had administered more than 220 crore COVID vaccine doses by 6 January 2023, and it also noted that this scale was enabled by the CoWIN platform, which handled a massive beneficiary base and improved the efficiency of outreach and certification. Public trust was reinforced because people could see vaccination becoming a nationwide civic effort rather than a fragmented medical intervention, with campaigns designed to reach households, lagging districts, and populations that had delayed second or precaution doses.

For instance, the Union Health Ministry stated that the Har Ghar Dastak campaign led to a 5.9 rise in first dose coverage and an 11.7 rise in second dose coverage by 30 November 2021, clearly showing that direct, community-facing awareness efforts translated into measurable uptake. This combination of official communication, digital transparency, and last-mile mobilization helped India convert awareness into action, which in turn sustained vaccine acceptance and kept the market active even as the pandemic response evolved.

Rise in Vaccine Research and Development

The rise in vaccine research and development has remained a central driver of the India coronavirus vaccine market because continuous scientific progress has expanded product choices, strengthened confidence in safety and efficacy, and created a foundation for booster strategies, age-group expansion, and future-ready immunization planning. India’s R and D progress was shaped by close collaboration among government institutions, biotech companies, and regulatory bodies, allowing vaccine candidates to move from laboratory work to clinical trials and then into deployment with unusual speed for a public health emergency.

The Department of Biotechnology stated that Mission COVID Suraksha delivered four indigenous vaccines in just two years, augmented Covaxin manufacturing, and created infrastructure for the smoother development of future vaccines, which shows that demand was supported by a deeper national innovation framework rather than by a one-time emergency push alone. Research also improved market confidence by generating transparent evidence from large Indian trials, helping people and policymakers make decisions based on locally relevant data instead of depending entirely on foreign studies.

For instance, the phase 3 trial of Covaxin developed by ICMR and Bharat Biotech covered 25,800 individuals across 21 sites and showed interim efficacy of 81 percent, giving India one of its strongest examples of how rigorous domestic research could directly strengthen vaccine credibility and adoption. With additional advances such as ZyCoV-D becoming the world’s first DNA vaccine for human use and newer platforms continuing to emerge, India’s vaccine market has been propelled by an R and D engine that keeps innovation visible, practical, and commercially relevant.

Download Free Sample Report

Key Market Challenges

Vaccine Hesitancy

The spread of false or misleading information about vaccines, their safety, and efficacy can create doubts and fears, leading to hesitancy. Previous healthcare initiatives, such as the polio vaccination campaign, have faced challenges in some regions of India, contributing to mistrust in vaccines. Some communities have specific beliefs or practices that influence their perception of vaccines. Overcoming these cultural and religious barriers is essential. In remote and underserved areas, limited access to information and healthcare services can lead to vaccine hesitancy due to a lack of awareness about the importance of vaccination.

Concerns about potential side effects or adverse reactions can deter individuals from getting vaccinated. Transparent reporting of side effect data is crucial to address these concerns. In some cases, people may trust traditional or alternative medicine over vaccines, leading to hesitancy. Challenges related to vaccine access, including long travel distances to vaccination sites, inadequate healthcare infrastructure, and lack of resources, can contribute to hesitancy. Effective communication from healthcare authorities is vital. Clear, accurate, and culturally sensitive messaging can address concerns and build trust in the vaccine. Public trust in the vaccine manufacturing and distribution process is essential. Ensuring transparency and adherence to strict safety and efficacy standards is crucial.

Supply Chain Issues

Some COVID-19 vaccines, especially those with specific temperature requirements, need reliable cold storage infrastructure to maintain their efficacy. Ensuring that this infrastructure is in place and functioning effectively has been a challenge, especially in remote and underserved areas. Transporting vaccines from manufacturing facilities to vaccination centers across a vast and diverse country like India poses logistical challenges. Maintaining the cold chain during transportation is essential to prevent vaccine spoilage.

Reaching remote and rural areas with vaccines has been a challenge due to limited transportation options and inadequate infrastructure. Ensuring equitable vaccine distribution to all regions is crucial. Proper packaging and labeling of vaccines are critical for tracking and ensuring their safety. Any issues with packaging and labeling can lead to complications in the supply chain. The global nature of vaccine supply chains meant that disruptions in the supply of key components, like glass vials and raw materials, could impact vaccine production and distribution. Maintaining accurate inventory and ensuring that vaccines do not go to waste due to expiration is a constant challenge.

Key Market Trends

Variants and Booster Shots

The emergence of new variants of the SARS-CoV-2 virus raised concerns about the effectiveness of existing vaccines. Variants like Delta and Omicron had the potential to impact vaccine efficacy. As a result, researchers and vaccine manufacturers were working to adapt vaccines to better address these new strains. The need for booster shots to enhance and prolong vaccine protection was being discussed and implemented. Booster doses were considered for individuals who had received their initial vaccine series, and the timing and frequency of booster shots were subjects of study and debate. The Omicron variant, which was first identified in late 2021, sparked particular concern due to its high number of mutations.

This led to a more urgent focus on booster strategies and potential modifications to existing vaccines. Vaccine manufacturers were conducting research to determine the effectiveness of their vaccines against variant strains. This research informed decisions about booster shots and potential updates to existing vaccines. The Indian government, like many others, was considering and implementing booster dose strategies and providing guidance on which vaccines to administer as booster shots. The discussion around booster shots and variants was an important part of public awareness campaigns, as it influenced people's understanding of the evolving situation and the importance of staying up to date with vaccinations. Some vaccine manufacturers were exploring the development of updated vaccines specifically designed to target prevalent variants more effectively.

Technological & Digital Innovation

Technological and digital innovation has played a transformative role in shaping the coronavirus vaccine market in India. A key breakthrough was the rapid development and deployment of diverse vaccine platforms, including viral vector-based, DNA-based, protein subunit, and mRNA vaccines. Bharat Biotech introduced Covaxin, an indigenous inactivated virus vaccine, while Zydus Cadila developed ZyCoV-D, the world’s first DNA-based COVID-19 vaccine for human use. Gennova Biopharmaceuticals advanced India’s position in mRNA technology with GEMCOVAC-19, reflecting the country's growing focus on cutting-edge biotech solutions. 

India also pioneered the use of intranasal vaccines, exemplified by Bharat Biotech's iNCOVACC. These innovations not only expanded delivery methods but also improved ease of administration and acceptance among populations. Cold chain infrastructure saw substantial upgrades, with IoT-enabled logistics systems ensuring temperature-sensitive vaccines were safely distributed across remote regions. Digital innovation, led by the government-backed CoWIN platform, revolutionized vaccine registration, scheduling, and certification.

The platform integrated real-time data management with public access, enabling seamless coordination among vaccine providers, government authorities, and citizens.It became a global model for digital immunization logistics, strengthening transparency and traceability. Artificial intelligence and data analytics were leveraged for demand forecasting, supply chain optimization, and monitoring adverse events post-vaccination. These tools enhanced responsiveness and efficiency, especially during peak phases of the immunization drive. Together, these technological strides not only enabled mass-scale vaccination in record time but also positioned India as a frontrunner in digital public health infrastructure, setting a benchmark for future vaccine rollouts and broader healthcare innovations.

Segmental Insights

Type Insights

In 2024, the India Coronavirus Vaccine Market largest share was held by mRNA Based segment and is predicted to continue expanding over the coming years. mRNA vaccines were known for their high efficacy in clinical trials, which may have led to increased demand. Availability of mRNA vaccines through international agreements or partnerships with pharmaceutical companies could have increased their presence in the Indian market. Government decisions and agreements with vaccine manufacturers can also influence which vaccines are available in a particular market. The mRNA technology allows for relatively quick adjustments to vaccine formulations to address emerging variants, making them adaptable to changing circumstances.

Patient Type Insights

In 2024, the India Coronavirus Vaccine Market largest share was held by adults’ segment and is predicted to continue expanding over the coming years.  In most countries, including India, the initial phases of COVID-19 vaccination campaigns prioritized adults, particularly those in higher-risk categories, such as healthcare workers, the elderly, and individuals with underlying health conditions. This prioritization was based on the higher vulnerability of these groups to severe illness and complications from COVID-19. Vaccination campaigns often roll out in phases, starting with the most vulnerable and essential groups and then expanding to the broader adult population.

As the campaigns progress, more adults become eligible for vaccination, contributing to the larger share of the market. In demographic terms, the adult population is generally larger than the elderly or paediatric populations. Therefore, a vaccine market that includes adults naturally encompasses a larger portion of the population. Adults constitute a significant part of the workforce and are involved in various economic activities, making them a priority for vaccination to reduce the impact of the pandemic on the economy. Achieving herd immunity often relies on a substantial portion of the adult population being vaccinated, as they make up most of the population. This is essential for controlling the spread of the virus.

Download Free Sample Report

Regional Insights

South India dominated the India coronavirus vaccine market due to its advanced healthcare infrastructure, strong pharmaceutical manufacturing base, and proactive state-level health initiatives. States like Tamil Nadu, Karnataka, Andhra Pradesh, Telangana, and Kerala played a crucial role in both vaccine production and distribution during the pandemic. Hyderabad, in particular, emerged as a major vaccine manufacturing hub. It is home to leading biotech firms such as Bharat Biotech, Biological E, and Indian Immunologicals, which were instrumental in developing and supplying COVID-19 vaccines like Covaxin and Corbevax. This local manufacturing capacity gave South India a logistical advantage in vaccine availability and distribution.  

South Indian states have historically invested in robust public health systems, with higher numbers of primary healthcare centers, trained medical staff, and better cold chain infrastructure. These factors enabled efficient vaccine storage, handling, and delivery, even in rural and remote areas. Digital literacy and higher education levels in the region supported widespread adoption of the CoWIN platform, ensuring organized vaccination scheduling and record-keeping. State governments in South India also launched targeted awareness campaigns and mobile outreach programs to increase vaccine coverage.These combined strengths positioned South India as a leader in India’s COVID-19 vaccination efforts, both in terms of production and effective immunization rollout.

Recent Developments

• In October 2025, CEPI and Serum Institute of India launched a new collaboration to strengthen pandemic-response preparedness using Serum’s baculovirus vaccine platform, with H5N1 selected as the prototype target for a potential Disease X threat. In October 2025, although the program was not a COVID-19 product launch, it represented a breakthrough innovation in rapid-response vaccine development by one of India’s principal COVID-vaccine producers and was explicitly framed around future pandemic readiness.
• In May 2025, Bharat Biotech said it was prepared to restart production of its COVID-19 vaccines if needed amid concern over emerging variants, and it specifically highlighted both its injectable and intranasal platforms. In May 2025, the company said those platforms were designed to adapt to circulating strains and could be scaled up quickly, making this a significant company update tied directly to India’s indigenous coronavirus-vaccine capabilities.
• In January 2025, Primrose Bio and Serum Institute of India announced a collaboration to develop a novel multi-antigen vaccine, with Primrose handling strain development through its Pfenex Expression Technology and Serum Institute leading further development and commercialization. In January 2025, the update was relevant to India’s coronavirus-vaccine landscape because it involved Serum Institute, one of India’s most important COVID-19 vaccine manufacturers, expanding its platform partnerships for future large-scale vaccine programs.

Key Market Players

• Serum Institute of India Pvt. Ltd
• Bharat Biotech International Ltd.
• Zydus Cadila Ltd.
• Pfizer India Ltd
• Panacea Biotec Ltd
• Indian Immunologicals Ltd
• Mynvax Pvt. Ltd.
• Biological E Ltd.,
• Hetero Biopharma Ltd.
• Dr Reddy's Laboratories Ltd.

Report Scope:

In this report, the India Coronavirus Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

•      India Coronavirus Vaccine Market, By Type:

o   mRNA Based

o   Non-Replicating Viral Vector Based

o   Inactivated Vaccine

•    India Coronavirus Vaccine Market, By Patient Type:

o   Adult

o   Pediatric

•    India Coronavirus Vaccine Market, By End-User:

o   Hospitals

o   Clinics

o   Research Institutes

o   Others

•   India Coronavirus Vaccine Market, By Region:

o   North India

o   South India

o   East India

o   West India

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the India Coronavirus Vaccine Market.

Available Customizations:

India Coronavirus Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

India Coronavirus Vaccine Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]